OC
JSPR icon

Oppenheimer & Co’s Jasper Therapeutics JSPR Stock Holding History

Oppenheimer & Co’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,656
Closed -$148K – 1700
2025
Q2 		$148K Buy
+26,656
New +$131K ﹤0.01% 1537

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Oppenheimer & Co's JSPR Position: Q3 2025 in Review

Oppenheimer & Co sold out of Jasper Therapeutics (JSPR) in Q3 2025, closing a stake of 26,656 shares — an estimated $148K sold.

Oppenheimer & Co first reported a position in JSPR in Q2 2025 and held it in 1 quarter. The position peaked at $148K in Q2 2025. 60 funds tracked by Wall St. Rank hold JSPR as of Q3 2025.

  • Oppenheimer & Co reported no remaining Jasper Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Oppenheimer & Co sold 26,656 Jasper Therapeutics shares in Q3 2025, an estimated $148K.
  • Oppenheimer & Co first reported a position in Jasper Therapeutics in Q2 2025 and held it in 1 quarter.
  • Oppenheimer & Co's Jasper Therapeutics position peaked at $148K in Q2 2025.
  • 60 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2025.

Based on Oppenheimer & Co's 13F filing for Q3 2025, filed 6 Nov 2025.